Document is current
Any future updates will be listed below
-
Authors
Turner, Ashlee https://orcid.org/0000-0002-8919-4360
Hickie, Ian B https://orcid.org/0000-0001-8832-9895
Maguire, Sarah https://orcid.org/0000-0003-0754-9189
Tonini, Emiliana https://orcid.org/0000-0002-8582-0491
LaMonica, Haley M https://orcid.org/0000-0002-6563-5467
Varidel, Mathew https://orcid.org/0000-0002-1648-8317
Nichles, Alissa https://orcid.org/0000-0001-6404-7199
Zmicerevska, Natalia https://orcid.org/0000-0001-7649-4711
Scott, Jan https://orcid.org/0000-0002-7203-8601
Pantelis, Christos https://orcid.org/0000-0002-9565-0238
Nelson, Barnaby https://orcid.org/0000-0002-6263-2332
McGorry, Patrick D https://orcid.org/0000-0002-3789-6168
Wood, Stephen J https://orcid.org/0000-0003-4186-5919
Yung, Alison R https://orcid.org/0000-0002-0401-9791
Purcell, Rosemary https://orcid.org/0000-0002-7912-6073
Scott, Elizabeth M https://orcid.org/0000-0003-3907-0324
Iorfino, Frank https://orcid.org/0000-0003-1109-0972
-
Funding
Funding for this research was provided by:
The University of Sydney
- License Information
-
More Information
Article History
Received: 20 March 2025
Accepted: 25 January 2026
First Online: 17 March 2026
Declarations
:
: This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving study participants were approved by the Human Research Ethics Committees at the University of Melbourne and the University of Sydney. Written informed consent was obtained from all participants.
: IBH is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC), University of Sydney, which operates an early-intervention youth service at Camperdown under contract to headspace; has previously led community-based and projects supported by the pharmaceutical industry focussed on the identification and better management of anxiety and depression (Wyeth, Elil Lily, Sevier, Pfizer, AstraZeneca, Janssen, Cilag); and is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, Innowell Pty Ltd, which aims to transform mental health services through the use of innovative technologies. EMS is Principal Research Fellow at the Brain and Mind Centre, The University of Sydney; Discipline Leader of Adult Mental Health, School of Medicine, University of Notre Dame; a Consultant Psychiatrist and was the Medical Director, Young Adult Mental Health Unit, St Vincent’s Hospital (Darlinghurst) until January 2021. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier, Janssen and Eli-Lilly pharmaceuticals; participated in a national advisory board for the antidepressant compound Pristiq (manufactured by Pfizer); and was the National Coordinator of an antidepressant trial sponsored by Servier.
